Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.

With an at least $60 billion total addressable market, the liquid biopsy sector offers abundant opportunity for multiple companies to swim to the top. The six largest companies in the pool have just ...

Dynamic Biopsy non-invasively analyses dynamic biological processes within a specific organ or tissue to assess its health ...

Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and Sheba Medical Center, Israel's largest medical center consistently ranked as a Top 10 World's Best Hospital by Newsweek ...

Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

Tethis collaborates with Sheba Medical Center to advance AI-powered liquid biopsy in rectal cancer: Milan, Italy Tuesday, March 11, 2025, 13:00 Hrs [IST] Tethis S.p.A., a pioneer ...

In a statement, the UK medical device firm said its "liquid biopsy" approach "offers the prospect of a new era of personalised cancer care" and moves it closer to positioning Parsortix as a go-to ...